25th Annual National Conference
Printable Schedule-at-a-Glance (Updated: 09/28/16)
WEDNESDAY, OCTOBER 5, 2016
Up to 6.0 continuing education credits available.
ACPE UAN 0860-0000-16-006-L01-P/0860-0000-16-006-L01-T (.6 CEUs)
Registration and Continental Breakfast — 4th Floor Atrium
Welcome and Opening Remarks — Grand Portage Ballroom, 4th Floor
25 Years: The Biggest Changes in Health Care and What the Future May Hold, Alan Langnas, DO, Nebraska Medicine
Throughout the past quarter century, we have witnessed radical treatment advances such as the major developments in immunosuppression for organ transplantation; the public health and clinical benefits of statins; the impact of genomics on the entire field of medicine; the introduction of targeted biopharmaceuticals; the advent of oral antiviral agents for hepatitis C that are capable of cure; and the use of vaccines as cancer prevention. Additionally, the decrease of tobacco use has had a significant effect on prevention.
With cultural shifts, policy adjustments, the price of care and technological advances, the hospital industry has moved toward a more patient-empowered approach that prioritizes prevention, as it continues to evolve by streamlining and improving patient care.
Dr. Langnas will highlight the past 25 years of momentous advances and stunning innovations in health care that have ensued from the use of advanced technologies and life-saving approaches. He will also take a look down the road at what changes we may see in health care during the next decade and beyond.
A Cure for Diabetes? Innovations from Pancreas to Islet-Cell to Beta-Cell Transplantation, Dixon B. Kaufman, MD, PhD, FACS, University of Wisconsin School of Medicine and Public Health, University Hospital
The discovery of insulin transformed type 1 diabetes from a fatal disease to a manageable condition, but it remains a very serious chronic illness. Islet-cell or pancreatic transplantation can, in principle, cure type 1 diabetes, but lifelong immunosuppressive therapy is required and the lack of donor pancreas tissue has led to attempts to find alternative treatment of type 1 diabetes. This session will discuss the Clinical Islet Transplantation Consortium (CIT) study and the advances in pancreatic-islet-cell transplant and kidney/pancreas transplant. It will also explore the utility of stem-cell-derived beta cells for future treatment of diabetes and the challenges faced in developing beta-cell replacement therapies.
Break — 4th Floor Atrium
Developments and Advances in Medical Management of Diabetes, Anne Peters, MD, Keck School of Medicine of USC
Morbidity from diabetes involves both macrovascular (atherosclerosis) and microvascular (retinopathy, nephropathy, and neuropathy) diseases. Interventions can limit organ damage and, therefore, patients with diabetes require initial and ongoing evaluation for diabetes-related complications. Weight management and the prevention of cardiovascular morbidity is a major priority for patients with diabetes, especially type 2 diabetes mellitus (T2DM). This session will analyze why glycemic control is important in the long term to reduce the onset and severity of the complications of type 2 diabetes, as well as to reduce macrovascular risk. It will also discuss the significant metabolic benefit of medications that are used to aid in weight loss in the management of diabetes and review medical management approaches consistent with guidelines from the American Diabetes Association (ADA) for health maintenance in patients with diabetes.
Exhibit Hall Grand Opening and Lunch — Exhibit Hall, 4th Floor
Current Issues in HIV: Successes, Challenges and Epidemic Trends, Timothy Schacker, MD, University of Minnesota
The first benchmark along the continuum of human immunodeficiency virus (HIV) care is diagnosis. At the time of HIV diagnosis, patients should be evaluated to assess the stage of the disease and establish a baseline to help determine management plans and goals. Timely linkage to care following diagnosis is the next step, and the more quickly newly diagnosed individuals enter HIV care, the better their health outcomes. Antiretroviral therapy (ART) may be initiated more promptly, with a subsequent reduction in viral load, which leads to improved health outcomes and a reduction in HIV transmission. To achieve optimal clinical outcomes and to realize the potential public health benefit of treatment as prevention, attention to each step in the treatment cascade is critical. Given the many available assessment strategies and interventions, the challenge for the treatment team is to select the techniques that best fit each patient and patient population. This session will discuss how interdisciplinary teams of health care providers can address the timeliness of treatment and encourage adherence to ART, including programs in place through local and state health departments.
Relationship Between Physical and Mental Health in Children and Adolescents, Barry Sarvet, MD, The University of Massachusetts Medical School at Baystate
Medical science increasingly recognizes the vital link between physical and mental health. Consequences of adverse experiences are major risk factors for the leading causes of psychological and physical illness in children and adolescents. Adolescent psychological problems are often accompanied by physical symptoms. A prevalent mental disorder experienced among adolescents is depression, and a disturbing potential consequence of adolescent mental health disorders is the incidence of suicide. Prevention requires a comprehensive approach that influences all levels of the social ecology, including community involvement, relationships among families and neighbors, and individual behaviors. This session will identify the relationship between physical and mental health and its impact on children and adolescents.
Break — Exhibit Hall, 4th Floor
Reducing the Burden of Heart Failure: Patient-Centered Care and Process Improvement, Michael Petty, PhD, RN, CCNS, ACNS-BC, University of Minnesota Health
According to the CDC, 5.1 million Americans are currently diagnosed with congestive heart failure (CHF) at a cost of $32 billion dollars per year. Half of these patients will die within five years of diagnosis. Despite the seriousness of this condition, health care providers struggle with how to diagnose, treat, and manage complications in patients with heart failure. During this session, Dr. Petty will review the importance of interdisciplinary teams of health care providers to effectively communicate with marginalized populations — including older adults, patients with advanced heart failure, and long-term care residents — about their prognosis, emergency situations, and advanced-care planning as forms of patient-centered care for heart failure. Treatment options for optimal management of heart failure will also be reviewed.
Hematopoietic Cell Transplant (HCT): Moving Beyond Survival — The Patient’s Perspective, Linda Burns, MD, National Marrow Donor Program (NMDP)/Be The Match; Jan Perske, Bone Marrow Transplant Recipient Mom and Caregiver; Greta Perske Hokanson, Bone Marrow Transplant Recipient; Ed Plass, Double Cord Blood Transplant Recipient; and Kate Plass, Transplant Recipient Spouse and Caregiver
HCT is a complex and costly treatment that is often the only potentially curative therapy available for patients with hematologic malignancies and genetic/immune disorders. Transplant recipients and their caregivers often experience new physical, emotional, social and financial challenges posttransplant. NMDP/Be The Match is partnering with the transplant community to better understand what matters most to recipients and caregivers and to develop a patient-reported-outcomes HCT research agenda. This unique panel session of transplant recipients and their caregivers will provide you with a very personal view into the triumphs and challenges of receiving this life-saving treatment.
Optum Provider Network Reception — 6th Floor, Minnesota Room
THURSDAY, OCTOBER 6, 2016
Up to 5.0 continuing education credits available.
ACPE UAN 0860-0000-16-007-L01-P/0860-0000-16-007-L01-T (.5 CEUs)
9th Annual Wellness Walk — Check in at 4th Floor Registration Desk
Registration and Continental Breakfast — Exhibits Open (optional) — 4th Floor
Welcome and Opening Remarks — Grand Portage Ballroom, 4th Floor
Frontiers in Medicine
Manipulating the Microbiome: Potential Future Applications, David F. Mercer, MD, PhD, FRCS(S), Nebraska Medicine
The human microbiota has attracted attention as one of the most intriguing and underexplored areas of medical research. While there have been several promising avenues for future development of the microbiome, microbial replacement therapies will likely become standard practice as we further understand the possibilities, limitations, and implications of the microbiome. This session will discuss human microbiome and the role of microbiota and its new clinical applications.
Hand Transplantation: Developing an Innovative Therapy, Linda C. Cendales, MD, Duke University Medical Center
The first successful hand transplantation took place in 1998 and since this time there have been close to 100 such operations performed. In 1999, Dr. Cendales, the only hand transplant surgeon in the U.S. trained in both hand and microsurgery and hand transplantation, helped organize the team that performed the first U.S. hand transplant. During this presentation, Dr. Cendales will provide an overview of the history of hand transplantation, which, like other forms of organ transplantation, is a major surgical procedure requiring lifelong immunosuppression to prevent rejection of the transplanted hand.
Break — Exhibit Hall, 4th Floor
Understanding Myeloma Genetics May Lead to Individualized Therapies, Brian Van Ness, PhD, University of Minnesota Cancer Center; Jenny Ahlstrom, Myeloma Crowd and CrowdCare Foundation
The treatment of multiple myeloma (MM) is complex because of rapid advances in stem-cell transplantation, medications, and better supportive care, all of which have led to improved patient survival. Overall, the care of patients should focus on treatment of the disease process and any associated complications. The diagnostic criteria for and management of MM in the updated 2016 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) broadens the population of patients eligible for therapy by expanding the active myeloma category and also integrating novel therapies at all stages of the disease. Dr. Van Ness will review current and new therapeutic approaches for the treatment of MM and will address the challenges that exist in the treatment of this disease. He will also identify genetic approaches to characterize variations in tumor progression and will address how to determine the best therapy to maximize effectiveness and response for each individual patient.
The Myeloma Crowd and CrowdCare Foundation were created by Jenny Ahlstrom after she was diagnosed with myeloma. On realizing that less than 5 percent of patients joined clinical trials, she started Myeloma Crowd Radio and began interviewing myeloma experts who share the latest research and open clinical trials in patient-friendly language in order to encourage participation in clinical trials. She has now held over 80 interviews with over a million listeners/readers. During this session, Ms. Ahlstrom will discuss how Myeloma Crowd believes that educated and involved patients can drive better outcomes for themselves, be part of the solution to better care, and accelerate the discovery of a cure for their own disease.
Hepatitis C Virus (HCV): Treatment Guidelines to Screen and Diagnose for Optimal Management, Paul Kwo, MD, Stanford University
Chronic infection with the HCV primarily harms the liver, with liver cancer being a well-known consequence in some individuals — especially those who already have cirrhosis. Recent advances in the number and types of medications available to treat hepatitis C provide more options to consider when deciding on a treatment plan. Until a few years ago, there were only a few drugs approved by the FDA to treat hepatitis C, but newly available drugs have revolutionized treatment. These advances have made treatment regimens shorter in duration, less difficult to tolerate and more effective. This session will discuss the most recent evidence-based treatment guidelines to screen, diagnose and manage patients with HCV. Potential barriers to care will also be identified, as well as the latest pharmaceutical interventions for the treatment of HCV.
New! Special Guest Keynote Luncheon Presentation, Richard Migliori, MD, Executive Vice President of Medical Affairs and Chief Medical Officer, UnitedHealth Group— Grand Portage Ballroom (This session is not accredited; lunch is provided.)
Dessert Reception — Exhibit Hall, 4th Floor
Evolving Concepts in Cancer Immunotherapy: Prospects for a Cure, Matthew A. Lunning, DO, University of Nebraska Medical Center
In the last few decades, immunotherapy has become an important part of treating some types of cancer. Different types of immunotherapy include monoclonal antibodies, cancer vaccines, chimeric-antigen receptor (CAR) T-cell therapy and immune-checkpoint inhibitors. This session will describe the various types of immunotherapy and outline their clinical applications. The underlying principles of tumor immunology and immunotherapy will be discussed, as well as the appropriate selection of patients and the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.
Incompatible Kidney Transplantation: National Strategies and Outcomes, Dorry Segev, MD, PhD, Johns Hopkins University
The considerable shortage of organ donors and increasing number of patients with end-stage renal disease has led to an extended waiting time for potential renal-allograft recipients. ABO-incompatible kidney transplantation was previously considered to be an absolute contraindication for patients with end-stage kidney disease (ESKD) due to hyperacute rejection related to blood-type barrier. With the need to expand the donor pool and minimize shortage of kidneys for transplantation, ABO-incompatible kidney transplantation (ABOi KT) was introduced. Another way to offset the extended waiting time and shortage of organ donors is Kidney Paired Donation (KPD) as a transplant option for candidates who have a living donor who is medically able, but cannot donate a kidney to their intended candidate because the two individuals are physiologically incompatible.
Age Over 70: Heart Transplant or Ventricular-Assist Device (VAD)? Joseph G. Rogers, MD, Duke University Medical Center; and Jeffrey Teuteberg, MD, University of Pittsburgh Medical Center
Dramatic advances in VAD design and patient management have made mechanical circulatory support an attractive therapeutic option for the growing pool of elderly heart failure patients. There are three major indications for the use of VADs: 1) as a bridge to transplantation; 2) as a lifelong support alternative for patients deemed ineligible for heart transplantation, or so-called destination therapy; and 3) as a bridge to myocardial recovery. One of the most controversial issues in the field of patient selection for advanced heart failure is age. Many health care professionals are reluctant to list “elderly” candidates for transplant though the cutoff age varies. In contrast, there is no absolute age cutoff for VADs, and older patients may have easier access to mechanical pumps than to donor organs. During this session, two experts will debate the point/counterpoint for VAD-versus-heart transplant for this patient population. The criteria for patient selection for transplant and VADs, long-term survival and quality of life will be compared.
25th Anniversary Gala—6th Floor
Support for the Gala is provided by UW Health Transplant Program and City of Hope National Medical Center.
FRIDAY, OCTOBER 7, 2016
Up to 2.75 continuing education credits available.
ACPE UAN 0860-0000-16-008-L01-P/0860-0000-16-008-L01-T (.275 CEUs)
Optum Client Breakfast Discussion: Patient and Donor Perspectives on Bone Marrow Transplantation — 6th Floor, Minnesota Room — (Ticketed, nonaccredited event; by invitation only.)
Continental Breakfast — 4th Floor Atrium
The Business of Transplant: A Conversation with Experts, Michael Abecassis, MD, MBA, Northwestern University; C. Fred LeMaistre, MD, Sarah Cannon; John P. Roberts, MD, University of California, San Francisco Medical Center; and Elizabeth A. Pomfret, MD, University of Colorado Anschutz Medical Center
This session will feature a panel of experts who will discuss their experience in developing a value-based model for transplantation, as well as how this model is being emulated by other disciplines in health care. The impact of the Affordable Care Act (ACA) on this field of medicine will also be explored.
Break — 4th Floor Atrium
How to Improve Quality and Value in Health Care, Fred LeMaistre, MD, Sarah Cannon
Transplantation leads to better health, increased activity and an improved quality of life for most recipients. Transplant success can be highly dependent upon transplant timing and referral along with coordination of care for optimal outcomes posttransplant. One barrier to transplant is the lack of coverage options for many American seniors, who are unable to afford or access transplant because of out-of-pocket costs and outdated Medicare reimbursement policies. This session will discuss the importance of appropriate, timely delivery of care and explain gaps in care along with the challenges and barriers that impede access to these life-saving procedures.
Controversies in Transplantation: A Panel Discussion, Michael Abecassis, MD, MBA; Elizabeth A. Pomfret, MD; John P. Roberts, MD; and Joseph G. Rogers, MD
Note: OptumHealth Education reserves the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.
Last updated: 09/23/16